Tags
- 2041
- 3
- A
- Acceptance
- Achievement
- Actual
- Acute
- Administration
- Adult
- Advanced
- Adverse
- Adverse event
- Adverse Events
- Agreements
- Agriculture in the United States
- Allotransplantation
- Anticipation
- Anti-inflammatory
- Application
- Approval
- Approved
- Arm
- Arms
- Asset
- Australia
- Australian
- Australian Securities Exchange
- Authorized
- Back pain
- Based on
- Being
- Benefit
- Benefits
- Biologic
- Biologics license application
- Biopharmaceutical
- Broad
- Candidate
- Capital
- Capital requirement
- Cause
- Cell
- Cell Therapy
- Cellular
- Chief
- Chief executive
- Children
- China
- Chronic
- Clinical
- Clinical trial
- Clinical Trials
- Collaboration
- Collaborations
- Commerce
- Commercialization
- Competition
- Competitors
- Complete
- Contact
- Counter
- Covering
- Criteria
- Cryopreservation
- Damaging
- Death
- Defender
- Defined
- Development
- Development programs
- Differences
- Disease
- Distinct
- Drug
- Effector
- Enrollment
- Enter
- Establishment
- Estimate
- Estimates
- Europe
- Exchange
- Executive
- Expense
- Expression
- Factor
- Failure
- FDA
- Federal securities laws
- Fifth
- Filing
- Finance
- Financial performance
- Financial regulation
- Food
- Food and Drug Administration
- Forward-looking
- Forward-looking statement
- Future Development
- Future events
- Gastrointestinal tract
- Global leader
- Globe
- GlobeNewswire
- Graft
- Graft-versus-host disease
- Guarantee
- Harbor
- Heart
- Heart failure
- Host
- If
- Immune
- Immune system
- Implied
- Include
- Includes
- Indication
- In Europe
- Inflammation
- Inflammatory
- Inflammatory bowel disease
- Information Please
- Infringement
- Initiation
- In Japan!
- Intellectual
- Intellectual Property
- Investing.com
- Involve
- Japan
- Known
- Known and Unknown: A Memoir
- Lawsuit
- Leader
- Lethality
- Levels
- Leverage
- License
- Licensee
- Likelihood function
- Lineage
- Listed
- Low back pain
- Maintenance, repair and operations
- Manufacturing
- Market
- Marketing
- Medicine
- Mesenchyme
- Mesoblast
- Modulate
- Most
- MSB
- Multinational
- NASDAQ
- Need
- Needs
- New
- News agency
- New York
- Next
- Obligation
- Off-the-shelf
- Pain
- Partnership
- Patient
- Pediatric patient
- Pediatrics
- Perception
- Perceptions
- Performance
- Pharmaceutical drug
- Phase
- Phase 3
- Place
- Planning
- Platform
- Portfolio
- Potential benefits
- Pre-clinical development
- Press release
- Pricing
- Private Securities Litigation Reform Act
- Product
- Product marketing
- Property
- Property rights
- Proprietary
- Protection
- Provision
- Provisioning
- Public perception
- Public perceptions
- Reduction
- Reform
- Reform Act
- Refractory
- Regulation
- Reimbursement
- Relate
- Reliance
- Requirement
- Research
- Research and development
- Result
- Revenue
- Revise
- Rights
- Right to property
- Risk
- Risk factor
- Safe
- Safeco Field
- Safe Harbor
- Safe harbor provision
- Safe harbor provisions
- Scope
- SEC
- Securities litigation
- Security
- Severity
- Singapore
- Skill
- Source
- Statements
- Statistical significance
- Stem cell
- Steroid
- Stock exchange
- Strategic collaboration
- Strategic collaborations
- Strategy
- Stromal cell
- Strong
- Surrounding
- Technology
- Technology platform
- The australian
- The fifth
- The Immune
- The Initiation
- Therapy
- Timing
- Today
- Trials
- United State
- Unknown
- Versus
- Withdrawal
- World leader
- Worldwide
- Yield